)
Relmada Therapeutics (RLMD) investor relations material
Relmada Therapeutics Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Clinical-stage biotech focused on NDV-01 (bladder cancer) and sepranolone (Prader-Willi, Tourette, tremor).
Reported robust 12-month Phase 2 data for NDV-01 in NMIBC, showing high complete response rates and durable efficacy, especially in BCG-unresponsive patients.
Terminated esmethadone and psilocybin programs in 2025 after strategic review.
NDV-01 in Phase 2; Phase 3 RESCUE registrational program and IND filing planned for mid-2026.
Sepranolone Phase 2b study in PWS expected to start mid-2026.
Financial highlights
Net loss of $19.1M for Q1 2026, compared to $17.6M in Q1 2025.
Operating expenses rose to $19.5M from $18.2M year-over-year.
R&D expense decreased to $8.1M from $12.0M year-over-year, mainly due to lower study costs and program terminations.
General and administrative expense increased to $11.4M from $6.3M year-over-year, mainly from higher compensation and consulting.
Interest/investment income increased to $960K from $440K year-over-year.
Outlook and guidance
Cash runway expected to fund operations through 2029, including completion of NDV-01 Phase 3 RESCUE program.
Key milestones expected in 2026: NDV-01 IND filing, Phase 3 trial initiations, and sepranolone Phase 2b start.
Initial 3-month NDV-01 Phase 3 data from 2L BCG-unresponsive study anticipated by year-end 2026.
- NDV-01 demonstrates high response rates in NMIBC, with pivotal trials and strong financial backing ahead.RLMD
Company presentation12 May 2026 - NDV-01 delivers strong efficacy and safety in bladder cancer, with pivotal trials and funding secured.RLMD
Leerink Global Healthcare Conference 202630 Apr 2026 - A strategic pivot and successful financing in 2025 set the stage for renewed growth and shareholder value.RLMD
Proxy filing17 Apr 2026 - Key votes include director elections, equity plan expansion, and increasing authorized shares.RLMD
Proxy filing17 Apr 2026 - Shareholders will vote on key governance, compensation, and capital structure changes after a pivotal turnaround.RLMD
Proxy filing6 Apr 2026 - Biotech pivots pipeline, raises $160M, and registers 33.7M shares for investor resale.RLMD
Registration filing3 Apr 2026 - NDV-01 demonstrates high efficacy in NMIBC; Phase 3 trials and strong cash position support growth.RLMD
Corporate presentation1 Apr 2026 - NDV-01 phase II shows 76% 12-month CR and $160M financing supports phase III launch.RLMD
Q4 202520 Mar 2026 - NDV-01 delivers high response rates in NMIBC, with Phase 3 trials and strong financial runway ahead.RLMD
Corporate presentation19 Mar 2026
Next Relmada Therapeutics earnings date
Next Relmada Therapeutics earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Explore our global coverage
)
)